Recent Advances in Combretastatin A-4 Inspired Inhibitors of Tubulin Polymerization: An Update

BAYTAŞ S.

CURRENT MEDICINAL CHEMISTRY, cilt.29, sa.20, ss.3557-3585, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 29 Sayı: 20
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2174/1871526522666220105114437
  • Dergi Adı: CURRENT MEDICINAL CHEMISTRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.3557-3585
  • Anahtar Kelimeler: Combretastatin A-4, microtubules, cancer, drug development, tubulin polymerization inhibitors, MTAs, POTENT ANTITUMOR-ACTIVITY, BIOLOGICAL EVALUATION, MOLECULAR DOCKING, ANTICANCER AGENTS, CONCISE SYNTHESIS, TUMOR-CELLS, DERIVATIVES, ANALOGS, DESIGN, APOPTOSIS
  • Gazi Üniversitesi Adresli: Evet

Özet

Cancer is one of the leading causes of fatality and mortality worldwide. Investigations on developing therapeutic strategies for cancer are supported throughout the world. The massive achievements in molecular sciences involving biochemistry, molecular chemistry, medicine, and pharmacy, and high throughput techniques such as genomics and proteomics have helped create new potential drug targets for cancer treatment. Microtubules are very attractive targets for cancer therapy because of the crucial roles they play in cell division. In recent years, lots of efforts have been put into the identification of new microtubule-targeting agents (MTAs) in anticancer therapy. Combretastatin A-4 (CA-4) is a natural compound that binds to microtubules' colchicine binding site and inhibits microtubule polymerization. Due to CA-4's structural simplicity, many analogs have been synthesized. This article summarises the new molecule development efforts to reach CA-4 analogues by pharmacophore group modifications, which have been reported since 2015.